Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ

Journal of the American Geriatrics Society1 May 2006Cited by 90 (Europe PMC)

PMID16696744DOI10.1111/j.1532-5415.2006.00695.xPepBankPUB-16696744

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studySafety outcome
In teriparatide-treated women aged 80 and older, the review found no unexpected treatment-emergent adverse events.
In plain wordsIn women aged 80 and older who received teriparatide, the review found no unexpected adverse events.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableUnexpected treatment-emergent adverse events at age 80 and older
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
20 mug daily · self-injection · median 19 monthsAs given in this study (human).
Source sentences
Summary
The most important TEAEs in women aged 80 and older (23 patients from the placebo group and 25 patients from the teriparatide group) were also reviewed; no unexpected TEAEs were found in the patients treated with teriparatide.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
Report a problemFND-1669674413

Studies that did not test the peptide alone11

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic postmenopausal women, the teriparatide effect on bone turnover markers showed no significant treatment-by-age interaction.
In plain wordsIn women with osteoporosis, teriparatide's effect on bone turnover markers did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone turnover markers treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
4 context sentences(design, population, supporting numbers)
Summary · context
The effects of teriparatide on bone mineral density (BMD) of the lumbar spine and femoral neck; the incidence of new vertebral and new nonvertebral fragility fractures; bone turnover markers, including bone-specific alkaline phosphatase; and urinary deoxypyridinoline corrected for creatinine clearan…
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674401
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic postmenopausal women, the teriparatide effect on femoral neck BMD showed no significant treatment-by-age interaction.
In plain wordsIn women with osteoporosis, teriparatide's effect on femoral neck bone density did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674403
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic postmenopausal women, the teriparatide effect on vertebral fractures showed no significant treatment-by-age interaction.
In plain wordsIn women with osteoporosis, teriparatide's effect on vertebral fractures did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fractures treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674404
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic postmenopausal women, the teriparatide effect on nonvertebral fragility fractures showed no significant treatment-by-age interaction.
In plain wordsIn women with osteoporosis, teriparatide's effect on nonvertebral fragility fractures did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonvertebral fragility fractures treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674405
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporotic postmenopausal women, the teriparatide effect on height loss showed no significant treatment-by-age interaction.
In plain wordsIn women with osteoporosis, teriparatide's effect on height loss did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHeight loss treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674406
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In osteoporotic postmenopausal women, hyperuricemia showed no significant treatment-by-age interaction with teriparatide.
In plain wordsIn women with osteoporosis, the teriparatide versus placebo effect on hyperuricemia did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHyperuricemia treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Adverse events · Whole body
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674407
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In osteoporotic postmenopausal women, hypercalcemia showed no significant treatment-by-age interaction with teriparatide.
In plain wordsIn women with osteoporosis, the teriparatide versus placebo effect on hypercalcemia did not differ significantly between age groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHypercalcemia treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Adverse events · Whole body
Source sentences
Summary
There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674408
09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In osteoporotic postmenopausal women, back pain showed no treatment-by-age interaction with teriparatide.
In plain wordsIn women with osteoporosis, the teriparatide versus placebo effect on back pain showed no interaction with age.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBack pain treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Adverse events · Whole body
Source sentences
Summary
There were no treatment-by-age interactions for important treatment-emergent adverse events (TEAEs), including back pain, nausea, leg cramps, and dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674409
10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In osteoporotic postmenopausal women, nausea showed no treatment-by-age interaction with teriparatide.
In plain wordsIn women with osteoporosis, the teriparatide versus placebo effect on nausea showed no interaction with age.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNausea treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
There were no treatment-by-age interactions for important treatment-emergent adverse events (TEAEs), including back pain, nausea, leg cramps, and dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674410
11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In osteoporotic postmenopausal women, leg cramps showed no treatment-by-age interaction with teriparatide.
In plain wordsIn women with osteoporosis, the teriparatide versus placebo effect on leg cramps showed no interaction with age.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLeg cramps treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Adverse events · Musculoskeletal
Source sentences
Summary
There were no treatment-by-age interactions for important treatment-emergent adverse events (TEAEs), including back pain, nausea, leg cramps, and dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674411
12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In osteoporotic postmenopausal women, dizziness showed no treatment-by-age interaction with teriparatide.
In plain wordsIn women with osteoporosis, the teriparatide versus placebo effect on dizziness showed no interaction with age.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDizziness treatment-by-age interaction
Study
n: not reported in source
Comparator
Treatment-by-age interaction, younger than 75 versus 75 and older
Outcome group
Adverse events · Nervous system and cognition
Source sentences
Summary
There were no treatment-by-age interactions for important treatment-emergent adverse events (TEAEs), including back pain, nausea, leg cramps, and dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
Summary · context
Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 mug (N=541) by daily self-injection for a median of 19 months.
Summary · context
For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1669674412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.